Marinus Charts The Way Forward For Ganaxolone Amid Business Challenges

Phase II results for Marinus’s ganaxolone in postpartum depression are a mixed bag, but the US biotech sees potential in this and other neurological indications, probably with partners.  

Magnolia
Pink magnolias in bloom • Source: Shutterstock

An oral formulation of Marinus Pharmaceuticals Inc.’s lead product, ganaxolone, has produced disappointing results in two Phase II studies (MAGNOLIA and AMARYLLIS) in patients with postpartum depression, but an intravenous formulation has shown some promise.

The findings were associated with an almost 70% decline in the company’s share price on 23 July as the US...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category